nosocomi
commun
set
could
also
occur
hadvattribut
mortal
approxim
howev
dissemin
case
rate
may
increas
major
risk
factor
sever
invas
hadv
diseas
dissemin
tcell
deplet
includ
ex
vivo
tcell
deplet
use
alemtuzumab
younger
age
unrel
donor
graft
cord
blood
prolong
immunosuppress
treatment
absolut
lymphocyt
count
alc
addit
risk
factor
background
european
societi
infecti
diseas
leukemia
recommend
routin
hadv
monitor
use
quantit
polymeras
chain
reaction
pcr
peripher
blood
especi
highrisk
patient
howev
correl
hadv
speci
clinic
featur
immunocompromis
popul
establish
yet
hadv
caus
varieti
clinic
manifest
depend
viru
type
tissu
tropism
immunocompet
host
exampl
speci
c
e
caus
respiratori
ill
wherea
speci
f
g
mainli
caus
gastroenter
speci
eg
hadv
respons
urinari
tract
infect
speci
b
known
associ
keratoconjunct
seriou
complic
often
result
lower
respiratori
tract
ill
particularli
associ
hadv
speci
b
hypothes
hadv
type
could
also
affect
clinic
featur
includ
sever
andor
dissemin
allogen
hct
recipi
main
object
studi
investig
epidemiolog
hadv
infect
clinic
correl
hadv
type
among
korean
pediatr
allogen
hct
recipi
addit
explor
potenti
risk
factor
hadv
infect
viremia
hadvattribut
mortal
studi
conduct
samsung
medic
center
smc
seoul
korea
april
septemb
consecut
pediatr
recipi
age
less
year
receiv
allogen
hct
pediatr
cancer
center
agre
particip
includ
inform
consent
assent
obtain
time
enrol
studi
approv
institut
review
board
irb
smc
irb
recipi
screen
respiratori
viru
infect
admiss
hct
center
enrol
patient
blood
urin
stool
specimen
collect
prospect
infus
date
transplant
day
ml
edta
whole
blood
collect
weekli
day
transplant
day
day
day
etc
urin
stool
sampl
collect
weekli
well
blood
sampl
collect
specimen
store
dna
extract
day
urin
stool
specimen
test
whenev
clinic
suspect
hadv
detect
perform
addit
quantit
realtim
pcr
use
blood
specimen
detect
hadv
viremia
respiratori
specimen
test
use
multiplex
respiratori
viru
pcr
lg
life
scienc
korea
respiratori
symptom
present
part
routin
care
practic
dna
extract
aliquot
clinic
sampl
use
qiaamp
blood
stool
mini
kit
qiagen
hilden
germani
elut
dna
store
pcr
amplif
quantit
realtim
pcr
use
detect
hadv
blood
specimen
use
commerci
adenoviru
rgene
kit
argen
varhil
franc
lower
limit
quantit
copiesml
qualit
convent
pcr
perform
detect
hadv
urin
stool
specimen
use
premix
kit
bioneer
daejeon
korea
follow
manufactur
protocol
human
adenoviru
type
determin
sequenc
hypervari
region
hexon
gene
nest
pcr
perform
secur
suffici
hadv
dna
sequenc
use
previous
describ
method
minor
modif
method
sequenc
perform
direct
use
round
pcr
primer
softwar
gene
code
ann
arbor
mi
usa
basic
local
align
search
tool
blast
softwar
http
blastncbinlmnihgov
use
identifi
hadv
type
phylogenet
molecular
analys
conduct
use
mega
refer
hadv
strain
shown
tabl
epidemiolog
data
patient
characterist
includ
age
hct
sex
underli
diseas
type
donor
sourc
graft
use
total
bodi
irradi
tbi
use
antithymoglobulin
atg
condit
regimen
collect
medic
record
time
enrol
perform
weekli
monitor
clinic
data
includ
symptom
laboratori
data
sever
graftvshost
demograph
clinic
data
compar
use
fisher
exact
test
chisquar
test
categor
variabl
mannwhitney
u
test
continu
variabl
appropri
categor
variabl
present
frequenc
percentag
continu
variabl
summar
median
rang
logist
regress
analysi
perform
evalu
risk
factor
hadv
infect
viremia
relationship
potenti
risk
factor
outcom
test
cox
proportionalhazard
regress
variabl
p
univari
analysi
includ
multivari
analysi
model
also
includ
variabl
age
hct
sex
relaps
statu
underli
diseas
relaps
sever
acut
gvhd
grade
addit
multivari
analysi
model
ii
phylogenet
tree
gener
use
neighborjoin
april
septemb
total
pediatr
recipi
receiv
allogen
hct
smc
among
recipi
hct
procedur
enrol
figur
median
age
hct
year
rang
year
recipi
male
median
followup
year
rang
year
none
patient
receiv
ex
vivo
tcell
deplet
detail
characterist
list
tabl
total
blood
sampl
stool
sampl
urin
sampl
test
hadv
detect
sampl
recipi
tabl
cumul
incid
hadv
infect
day
year
year
confid
interv
ci
ci
ci
respect
figur
four
recipi
develop
hadv
viremia
cumul
incid
day
year
ci
ci
ci
respect
figur
median
time
hct
first
hadv
infect
day
rang
day
onset
hadv
viremia
day
rang
day
half
hadv
infect
occur
day
hct
hadvposit
respiratori
specimen
n
detect
day
tabl
among
hadvinfect
patient
experienc
relaps
underli
diseas
one
patient
recipi
separ
episod
hadv
infect
patient
develop
hadv
diarrhea
without
viremia
day
hct
develop
anoth
episod
hadv
infect
hadv
detect
urin
blood
day
hct
perform
year
hct
ten
hadv
infect
probabl
hadv
diseas
asymptomat
infect
enter
diarrhea
melena
n
respiratori
ill
n
common
clinic
manifest
follow
hematuria
n
asymptomat
condit
n
tabl
among
total
hadvdetect
sampl
sampl
avail
type
sequenc
repres
sampl
studi
tabl
among
hadv
commonli
detect
type
n
follow
hadv
n
one
case
hadv
respect
tabl
phylogenet
tree
hadv
shown
figur
type
analysi
hadv
type
detect
blood
variou
type
detect
stool
hadv
p
one
urin
specimen
type
hadv
tabl
note
differ
type
hadv
detect
sequenti
recipi
case
figur
one
patient
recipi
hadv
detect
blood
day
hadv
detect
stool
day
anoth
patient
recipi
hadv
detect
day
hadv
detect
day
stool
sampl
figur
univari
analysi
identifi
potenti
risk
factor
hadv
infect
tabl
case
hadv
viremia
n
extens
chronic
gvhd
identifi
risk
factor
univari
analysi
p
howev
unabl
appli
multivari
analysi
due
small
number
case
tabl
univari
analysi
categori
underli
diseas
relaps
state
underli
diseas
type
donor
intens
condit
regimen
use
atg
extens
chronic
gvhd
exist
hadv
viremia
identifi
potenti
risk
factor
mortal
p
hadv
viremia
appear
signific
risk
factor
mortal
univari
analysi
p
signific
multivari
analysi
result
studi
highlight
epidemiolog
find
differ
previou
studi
first
cumul
incid
hadv
viremia
lower
previou
studi
studi
cumul
incid
hadv
viremia
day
year
wherea
rate
report
previou
studi
pediatr
patient
one
possibl
explan
use
alemtuzumab
ex
vivo
tcell
recipi
admit
hospit
due
anemia
develop
fever
red
blood
cell
transfus
respiratori
multiplex
pcr
perform
routin
care
practic
speci
hadv
preval
speci
among
pediatr
hct
recipi
commun
infect
set
hadv
identifi
preval
genotyp
uk
croatia
wherea
hadv
identifi
preval
type
korea
result
type
analys
east
asian
countri
taiwan
japan
also
show
speci
b
especi
hadv
preval
commun
hadv
c
well
known
persist
infect
mucos
lymphocyt
tissu
henc
hadv
c
may
like
latent
state
transplant
link
earli
posthct
reactiv
differ
preval
specif
viru
type
commun
might
one
possibl
explan
incid
hadv
infect
studi
lower
previou
studi
european
countri
high
hadv
load
blood
known
import
risk
factor
diseas
sever
mortal
therefor
guidelin
recommend
quantit
pcr
monitor
hadv
peripher
blood
lion
et
al
report
fatal
case
associ
speci
c
among
austrian
pediatr
allogen
hct
recipi
relationship
hadv
type
clinic
sever
andor
dissemin
remain
uncertain
base
current
data
henc
studi
need
observ
interest
find
virustyp
analys
first
differ
type
hadv
detect
recipi
within
short
time
interv
recipi
figur
high
major
reason
refus
enrol
poor
complianc
includ
difficulti
collect
deliv
urin
stool
specimen
second
possibl
underestim
incid
hadv
infect
viremia
due
fact
routin
surveil
perform
day
hct
found
signific
number
hadv
infect
occur
posthct
day
lastli
size
studi
sampl
rel
small
demonstr
definit
risk
factor
hadv
infect
viremia
summari
observ
lower
incid
rate
delay
onset
pattern
hadv
infect
previou
studi
might
influenc
extent
tcell
deplet
andor
local
hadv
epidemiolog
hadv
common
type
follow
hadv
wherea
hadv
report
preval
type
western
countri
although
unabl
identifi
potenti
risk
factor
hadv
infect
viremia
found
hadvinfect
recipi
viremia
like
extens
chronic
gvhd
lower
lymphocyt
count
without
viremia
conclus
studi
demonstr
distinct
epidemiolog
hadv
korean
recipi
watch
monitor
hadv
viremia
recommend
hadvinfect
hct
recipi
particularli
sever
lymphopenia
extens
chronic
gvhd
addit
studi
necessari
clarifi
relationship
hadv
type
clinic
sever
rate
viremia
author
report
conflict
interest
disclos
